Drug Profile
Inetagugene geperpavec - Krystal Biotech
Alternative Names: HSV1-TGM1; KB-105Latest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference; Transglutaminase 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Ichthyosis
Most Recent Events
- 29 Feb 2024 Krystal Biotech has patent protection for the pharmaceutical composition comprising of replication defective HSV-1 vector encoding TGM and methods of delivering TGM in USA before February 2024
- 29 Feb 2024 Krystal Biotech has patent protection for the pharmaceutical composition comprising of herpes virus vector encoding TGM in Australia before February 2024
- 23 Feb 2023 Krystal Biotech plans phase II trial in Icthyosis (In infants, In adolescents, In children, In adults, In the elderly) in USA in March 2023 (Topical, Gel) (NCT05735158)